Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2014

View Archived Issues

hAT-MSCs partially restore corneal epithelial phenotype in an in vivo model of LSCD

Temozolomide causes biological and radiological improvements in pituitary carcinoma case study

Sanofi creates hybrid VEGF/PDGF soluble receptors for AMD

Novel bispecific antibody for the treatment of P. aeruginosa infection

Close-field electroporation gene delivery for damaged cochlear hair cells regeneration

Discovery of a unique bacterial zinc metalloprotease inhibitor

Beraprost sodium single isomer shows potential for influenza

KinoPharma and Carna Biosciences patent new DYRK1A inhibitors

Researchers at Zafgen design novel MetAP 2 inhibitors for obesity

Allergan reports discovery of S1P1 receptor ligands

Bristol-Myers Squibb and CytomX Therapeutics establish immune-oncology collaboration

BioCryst reports preliminary results from OPuS-1 study of BCX-4161 for HAE

Spark Therapeutics completes Series B financing

Novogen identifies compounds active against prostate cancer cells

Roche licenses rights to antibody engineering technologies from Chugai

MacroGenics and Takeda Pharmaceutical enter into option agreement for MGD-010

RaQualia Pharma researchers prepare and test Na channel blockers

U.S. investigators report development of HDAC inhibitors for AKI

TetraLogic selects phase II dose of birinapant for higher risk MDS

BMS and Incyte initiate phase I/II immunotherapy combination trial in cancer

Enrollment under way in phase I study of MEDI-7510 for RSV

European approval for Entyvio in ulcerative colitis and Crohn's disease

Xarelto filed in Japan for three indications

Valeant makes revised proposal to Allergan, plans to sell filler and toxin assets to Nestle

FDA grants fast track designation to obeticholic acid for primary biliary cirrhosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...